-- Mary Elizabeth Dallas
TUESDAY, Sept. 13 (HealthDay News) -- A treatment currently
being studied may prevent progression of atherosclerosis, a
condition caused by the build-up of plaque in artery walls that can
lead to heart attack, according to new research.
In conducting the study, published in the Sept. 12 issue of
The Lancet, researchers followed 130 patients with atherosclerosis who were randomly assigned to be treated with either the experimental heart drug dalcetrapib, or an inactive placebo over the course of two years. In the double-blind study, neither the researchers nor the patients knew who was taking the heart drug and who was taking the placebo.
While statin drugs are commonly used to lower LDL or "bad"
cholesterol to reduce the risk of coronary artery disease,
dalcetrapib raises HDL or "good" cholesterol in order to reduce the
risk, the researchers explained.
To determine the efficacy of dalcetrapib, the researchers used
non-invasive imaging technology. Through MRI, the researchers found
the patients on dalcetrapib had a 31 percent increase in "good" HDL
cholesterol levels. Additional PET/CT scans showed that
inflammation levels in the carotid artery of patients were
significantly reduced only among those taking dalcetrapib. The
carotid arteries are responsible for supplying oxygenated blood to
the head and neck.
In a different study, a drug in the same class designed to raise
HDL levels was tied to an increase in death linked to vascular
inflammation, but the researchers did not find an increase in such
inflammation with dalcetrapib.
"This milestone study shows that MRI and PET/CT are highly useful in assessing the safety and efficacy of dalcetrapib, and that this novel therapy may address a significantly unmet need in cardiovascular disease," said lead study author Zahi A. Fayad, a professor of radiology and medicine in the cardiology division at Mount Sinai School of Medicine and the director of its Translational and Molecular Imaging Institute, in a Mt. Sinai news release.
"We are excited about the results obtained in this trial, which could have a great impact on the treatment of patients with cardiovascular disease," said Fayad, who disclosed receiving financial compensation as a scientific advisory board member from the study's sponsor, Hoffmann-La Roche, whose holding company makes dalcetrapib.
Fayad noted imaging technology could be a vital tool for
evaluating other treatments for heart disease.
The U.S. National Library of Medicine has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.